XML 148 R49.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 12 Months Ended
Feb. 28, 2022
Dec. 10, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2018
Dec. 31, 2016
Loss Contingencies [Line Items]            
Proceeds from issuance of common stock     $ 493,481    
Purchase obligation     $ 399,000      
Stockholders' equity, reverse stock split   5-for-1        
Number of common stock issued     400,000      
Number of additional shares issued     100,000      
Harborside Advisors LLC [Member]            
Loss Contingencies [Line Items]            
Stock issued during period, shares, reverse stock splits   1,000,000        
Stock issued during period, shares, stock splits   200,000        
Revenue   $ 10,000,000        
Shares issued   1,000,000        
Incurred damages   $ 75,000        
Harborside Advisors LLC [Member] | Maximum [Member]            
Loss Contingencies [Line Items]            
Loss contingency, damages sought, value   33,020,000        
Harborside Advisors LLC [Member] | Minimum [Member]            
Loss Contingencies [Line Items]            
Loss contingency, damages sought, value   $ 5,020,000        
Conversion Labs Rx Business [Member]            
Loss Contingencies [Line Items]            
Stock issued during period, shares, stock splits   200,000        
Conversion Labs Rx Business [Member] | Maximum [Member]            
Loss Contingencies [Line Items]            
Stock issued during period, shares, stock splits   1,000,000        
Pilaris Laboratories, LLC [Member]            
Loss Contingencies [Line Items]            
Finite-lived intangible asset, useful life           10 years
Intercompany agreements, description           As consideration for granting Conversion Labs PR this license, Pilaris will receive on quarterly basis, 10% of the net income collected by the licensed products based on the following formula: Net Income = total income – cost of goods sold – advertising and operating expenses directly related to the marketing of the licensed products
Percentage of net income           10.00%
Accrued expenses     $ 138,000 $ 0    
Share based compensation arrangement by share based payment award, expiration period         10 years  
M.ALPHABET, LLC [Member]            
Loss Contingencies [Line Items]            
Intercompany agreements, description     The Company shall pay Alphabet a royalty equal to 13% of Gross Receipts (as defined in the Agreement) realized from the sales of Licensed Products. No amounts were earned or owed as of December 31, 2022      
Stock option to purchase shares         20,000  
Stock option exercise price         $ 2.50  
M.ALPHABET, LLC [Member] | Common Stock One [Member]            
Loss Contingencies [Line Items]            
Stock option to purchase shares         20,000  
Stock option exercise price         $ 2.50  
Proceeds from issuance of common stock         $ 7,500,000  
M.ALPHABET, LLC [Member] | Common Stock Two [Member]            
Loss Contingencies [Line Items]            
Stock option to purchase shares         20,000  
Stock option exercise price         $ 2.50  
Proceeds from issuance of common stock         $ 10,000,000  
M.ALPHABET, LLC [Member] | Common Stock Three [Member]            
Loss Contingencies [Line Items]            
Stock option to purchase shares         40,000  
Stock option exercise price         $ 3.75  
Proceeds from issuance of common stock         $ 20,000,000  
Conversion Labs Rx Business [Member] | Harborside Advisors LLC [Member]            
Loss Contingencies [Line Items]            
Stock issued in issuance costs   $ 5,000,000        
Conversion Labs Rx Business [Member] | Harborside Advisors LLC [Member] | Maximum [Member]            
Loss Contingencies [Line Items]            
Stock issued in issuance costs   5,000,000        
Conversion Labs Rx [Member]            
Loss Contingencies [Line Items]            
Contigency contract amount   $ 273,859        
Blair LLC [Member]            
Loss Contingencies [Line Items]            
Contigency contract amount $ 1,000,000